Last checked at 6 Jun 2023 07:00
RNS: RELEASE 6 June 2023
ImmuPharma PLC
("ImmuPharma" or the "Company")
Notice of AGM & Annual Report & Accounts
ImmuPharma PLC (LSE AIM: IMM), the specialist drug discovery and development company, confirms that the Notice of Annual General Meeting ("AGM") has today been posted to shareholders. The Annual Report and Accounts for the year ended 31 December 2022 has also been posted to shareholders today.
These documents will be available shortly, in electronic form, for download on the Company's website www.immupharma.co.uk.
ImmuPharma's AGM will be held on Friday 30th June 2023 @ 11:00am (BST) at: One Bartholomew Close, London, EC1A 7BL.
Ends
For further information please contact:
|
Notes to Editors
About ImmuPharma PLC
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
For additional information about ImmuPharma please visit www.immupharma.co.uk
ImmuPharma's LEI (Legal Entity Identifier) code: 213800VZKGHXC7VUS895